scholarly journals A regulatory mutant on TRIM26 conferring the risk of nasopharyngeal carcinoma by inducing low immune response

2018 ◽  
Vol 7 (8) ◽  
pp. 3848-3861 ◽  
Author(s):  
Xiao-Ming Lyu ◽  
Xiao-Wei Zhu ◽  
Manli Zhao ◽  
Xian-Bo Zuo ◽  
Zhong-Xi Huang ◽  
...  
Keyword(s):  
Immune Response ◽  
Nasopharyngeal Carcinoma ◽  
Regulatory Mutant

scholarly journals Exploration of a Novel Prognostic Risk Signature and Its Effect on the Immune Response in Nasopharyngeal Carcinoma

2021 ◽  
Vol 11 ◽  
Author(s):  
Shuang Zhao ◽  
Xin Dong ◽  
Xiaoguang Ni ◽  
Lin Li ◽  
Xin Lu ◽  
...  
Keyword(s):  
Immune Response ◽  
Nasopharyngeal Carcinoma ◽  
Risk Group ◽  
Progression Free Survival ◽  
Gene Signature ◽  
Metastatic Carcinoma ◽  
High Risk Group ◽  
Molecular Characteristics ◽  
Novel Gene ◽  
Kaplan Meier

Nasopharyngeal carcinoma (NPC) is a highly invasive and metastatic carcinoma with different molecular characteristics and clinical outcomes. In this work, we aimed to establish a novel gene signature that could predict the prognosis of NPC patients. A total of 13 significant genes between the recurrence/metastasis (RM) group and the no recurrence/metastasis (no-RM) group were identified by machine learning from RNA-Seq data including 60 NPC tumor biopsies. Based on these genes, a 4-mRNA signature (considering U2AF1L5, TMEM265, GLB1L and MLF1) was identified. Receiver operating characteristic (ROC) and Kaplan-Meier (K-M) analyses indicated that this signature had good prognostic value for NPC. The overall survival (OS) and progression-free survival (PFS) of the patients in the high-risk group were significantly shorter than those of the patients in the low-risk group (p = 0.00126 and p = 0.000059, respectively). The area under the ROC curve (AUC) values of the 4-mRNA signature were higher than those of T stage and N stage for OS (0.893 vs 0.619 and 0.582, respectively) and PFS (0.86 vs 0.538 and 0.622, respectively). Furthermore, the 4-mRNA signature was closely associated with cell proliferation and the immune response. The expression of GLB1L and TMEM265 was associated with the level of tumor-infiltrating immune cells (r > 0.4, p < 0.05). We have validated the model through measuring the expression levels of the 4-mRNA signature by qRT-PCR, in an independent cohort of NPC patients. Here, we report a novel gene signature that can serve as a new tool for predicting the prognosis of NPC patients.

scholarly journals Idronoxil combined with cisplatin rescues refractory immune response in nasopharyngeal carcinoma

2020 ◽  
Author(s):  
Ngar Woon Kam ◽  
Desmond Tae Yang Hung ◽  
Man Kin Yim ◽  
Ka Chun Wu ◽  
Xin Yuan Guan ◽  
...  
Keyword(s):  
Immune Response ◽  
Nasopharyngeal Carcinoma

Identification of nasopharyngeal carcinoma antigens that induce humoral immune response by proteomic analysis

2007 ◽  
Vol 1 (7) ◽  
pp. 688-698 ◽  
Author(s):  
Zhi-Qiang Xiao ◽  
Ying Chen ◽  
Bin Yi ◽  
Mao-Yu Li ◽  
Peng-Fei Zhang ◽  
...  
Keyword(s):  
Immune Response ◽  
Nasopharyngeal Carcinoma ◽  
Humoral Immune Response ◽  
Proteomic Analysis ◽  
Humoral Immune

The immune response to terminal protein of Epstein-Barr virus in nasopharyngeal carcinoma patients

1995 ◽  
Vol 121 (S1) ◽  
pp. S18-S18
Author(s):  
T. Afanasyeva ◽  
V. Stepina ◽  
N. Belousova ◽  
T. Kondratyeva ◽  
E. Gurtsevitch
Keyword(s):  
Immune Response ◽  
Nasopharyngeal Carcinoma ◽  
Epstein Barr Virus ◽  
Terminal Protein ◽  
Barr Virus ◽  
Epstein Barr

scholarly journals Association between Antibody Responses to Epstein-Barr Virus Glycoproteins, Neutralization of Infectivity, and the Risk of Nasopharyngeal Carcinoma

mSphere ◽  
2020 ◽  
Vol 5 (6) ◽  
Author(s):  
Qian-Ying Zhu ◽  
Xiang-Wei Kong ◽  
Cong Sun ◽  
Shang-Hang Xie ◽  
Allan Hildesheim ◽  
...  
Keyword(s):  
Immune Response ◽  
Nasopharyngeal Carcinoma ◽  
Humoral Immune Response ◽  
Epstein Barr Virus ◽  
Healthy Controls ◽  
Humoral Immune ◽  
Barr Virus ◽  
Ebv Infection ◽  
Epstein Barr ◽  
Antibody Levels

ABSTRACT While Epstein-Barr virus (EBV) is the major cause of nasopharyngeal carcinoma (NPC), the value of the humoral immune response to EBV glycoproteins and NPC development remains unclear. Correlation between antiglycoprotein antibody levels, neutralization of EBV infectivity, and the risk of NPC requires systematic study. Here, we applied a cytometry-based method and enzyme-linked immunosorbent assay to measure neutralization of infectivity and antibody response to EBV glycoproteins (gH/gL, gB, gp350, and gp42) of plasma samples from 20 NPC cases and 20 high-risk and 20 low-risk healthy controls nested within a screening cohort in Sihui, southern China. We found that NPC cases have similar plasma neutralizing activity in both B cells and epithelial cells and EBV glycoprotein-specific IgA and IgG antibody levels compared with those of healthy controls. Significant correlations were observed between gH/gL IgG and gB IgG and the neutralizing ability against EBV infection of epithelial cells and B cells. These results indicate that a high level of glycoprotein antibodies may favor protection against primary EBV infection, instead of being low-risk biomarkers for NPC in long-term EBV-infected adults. In conclusion, this study provides novel insights into the humoral immune response to EBV infection and NPC development, providing valuable leads for future research that is important for prevention and treatment of EBV-related diseases. IMPORTANCE Epstein-Barr virus (EBV) is a human oncogenic gammaherpesvirus that infects over 90% of humans in the world and is causally associated with a spectrum of epithelial and B-cell malignancies such as nasopharyngeal carcinoma (NPC). A prophylactic vaccine against EBV is called for, but no approved vaccine is available yet. Therefore, EBV remains a major public health concern. To facilitate novel vaccines and therapeutics for NPC, it is of great importance to explore the impact of humoral immune response to EBV glycoproteins before the development of NPC. Therefore, in this study, we systematically assessed the correlation between antiglycoprotein antibody levels, neutralization of EBV infectivity, and the risk of NPC development. These results provide valuable information that will contribute to designing effective prevention and treatment strategies for EBV-related diseases such as NPC.

Sign in / Sign up

Export Citation Format

Share Document